Nutrae Urolithin A pre-launch product presentation 01
Urolithin A · Capsules planned for the UAE private launch

Urolithin A

Urolithin A presented as a planned single-ingredient capsule with source-linked research context.

250 mg per capsule100 capsulesHalal statuscGMP status
AED 199SALES STARTING SOON

For three bottles, choose one of the four presentation gift boxes.

SALES STARTING SOON
Product facts

One molecule.
99% purity target.

The launch specification remains under final verification. The signed specification, COA, batch records and applicable certificates will be linked only after they are matched to the exact SKU and lot.

Target launch specification

Pending final verification
Active
Urolithin A
Release assay target
99% target
Target amount per capsule
250 mg
Target capsules per bottle
100
Capsule composition
Pending final signed specification
Excipient statement
Pending final signed specification
Filling and stability
Pending verification

View Certificate of Analysis · View Certifications · Batch-record status

Ingredient identity

Urolithin A is a defined ingredient. Nutrae keeps its planned capsule specification separate from studies of proprietary formulations.

Explore the complete record

The exact study form, dose, population, measured results and material boundaries are mapped in Nutrae Science.

Open the evidence record
Human evidence

Source-linked study context.

Selected external studies are summarized with their form and limits. No finding is attributed to the planned Nutrae capsule.

Randomized human study · Cell Reports Medicine 2022

Urolithin A study: selected endpoints and limits.

In a four-month study of 88 middle-aged adults using a proprietary formulation, selected leg-strength endpoints changed while other outcomes were not significant. It did not test a finished Nutrae capsule.

Participants
88
Study doses
500 or 1,000 mg/day
Duration
4 months
Full context
Mapped in Science
Read the primary study
Ca-AKG AED 199 NR AED 199 Urolithin A AED 199